| ²é¿´: 733 | »Ø¸´: 9 | ||
| ¡¾½±Àø¡¿ ±¾Ìû±»ÆÀ¼Û7´Î£¬×÷Õßnif-hooÔö¼Ó½ð±Ò 4.25 ¸ö | ||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | ||
[×ÊÔ´]
¡¾·ÖÏí¡¿Nature-×îÐÂÎÄÕÂLessons from 60 years of pharmaceutical innovation
|
||
|
Nature-×îÐÂÎÄÕÂLessons from 60 years of pharmaceutical innovation ½éÉÜÁ˽ü60ÄêÐÂÒ©ÁìÓòÖ®¸ïС£ Abstract | Despite unprecedented investment in pharmaceutical research and development (R&D), the number of new drugs approved by the US Food and Drug Administration (FDA) remains low. To help understand this conundrum, this article investigates the record of pharmaceutical innovation by analysing data on the companies that introduced the ~1,200 new drugs that have been approved by the FDA since 1950. This analysis shows that the new-drug output from pharmaceutical companies in this period has essentially been constant, and remains so despite the attempts to increase it. This suggests that, contrary to common perception, the new-drug output is not depressed, but may simply reflect the limitations of the current R&D model. The implications of these findings and options to achieve sustainability for the pharmaceutical industry are discussed. http://d.namipan.com/d/dd9cc1919a985407d4ddcaacf49b9cf19b4e76c1954e0500 |
» ²ÂÄãϲ»¶
²ÄÁÏÇóµ÷¼Á Ò»Ö¾Ô¸¹þ¹¤´ó×Ü·Ö298·Ö£¬Ç°Èý¿Æ223·Ö
ÒѾÓÐ5È˻ظ´
085600 286·Ö ²ÄÁÏÇóµ÷¼Á
ÒѾÓÐ6È˻ظ´
086502»¯Ñ§¹¤³Ì342Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁÏÇóµ÷¼ÁÒ»Ö¾Ô¸¹þ¹¤´ó324
ÒѾÓÐ7È˻ظ´
328Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
340Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Ò»Ö¾Ô¸Äϲý´óѧ324Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
Çóµ÷¼ÁÍÆ¼ö ²ÄÁÏ 304
ÒѾÓÐ15È˻ظ´
291Çóµ÷¼Á
ÒѾÓÐ19È˻ظ´
331»·¾³¿ÆÑ§Ó빤³ÌÇóµ÷¼Á
ÒѾÓÐ3È˻ظ´
yantaiapple
Ìú¸Ëľ³æ (Ö°Òµ×÷¼Ò)
- Ó¦Öú: 12 (СѧÉú)
- ½ð±Ò: 10326.8
- Ìû×Ó: 4354
- ÔÚÏß: 277.2Сʱ
- ³æºÅ: 391534
2Â¥2009-12-17 09:20:48
°×¿ªË®
ľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 4 (Ó×¶ùÔ°)
- ¹ó±ö: 0.014
- ½ð±Ò: 2323.8
- Ìû×Ó: 1379
- ÔÚÏß: 362.7Сʱ
- ³æºÅ: 16172
3Â¥2009-12-17 14:40:59
4Â¥2009-12-17 15:21:32
5Â¥2010-01-16 09:27:03
6Â¥2010-01-16 17:04:06
7Â¥2010-01-16 22:28:54
9Â¥2010-01-17 15:52:23
10Â¥2010-04-06 23:19:18
¼òµ¥»Ø¸´
rdcr8Â¥
2010-01-17 12:38
»Ø¸´
















»Ø¸´´ËÂ¥